An mRNA vaccine, a cousin to the COVID vaccines that blunted the pandemic, has entered human trials as a treatment for lung ...

▎药明康德内容团队编辑（来源：中国科学院动物研究所）mRNA疗法因研发周期短、生产成本低、制备工艺简单、起效快等优势，被广泛应用于疫苗研发、蛋白替代疗法和基因编辑等领域。脂质纳米颗粒（LNP）是目前递送mRNA的最佳载体之一，但LNP的靶向递送能力存 ...

We recently looked at Goldman Sachs’ List Of Stocks That Hedge & Mutual Funds Love & Hate: 28 Stocks On The Mutual and Hedge ...

The discovery of the first mRNA-stabilizing substance could pave the way for groundbreaking advancements in the development ...

A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

信使RNA ...

Prenatal gene therapy via mRNA LNPs fixes faulty genes in fetal brain cells in animal model of neurodevelopmental syndrome.

With exclusive FDA insight, the 4th mRNA Analytical Development & Quality Control Summit returns; uniting the Analytical, ...

CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...

站在mRNA技术历史与未来的交汇点上交叉点上，杭州医学所的全体科研人员想要成为驾马车的人，把握分子医学在中国的前进方向。这份“冲动”并非为了金钱与名利，而是想要从分子的层面真正地、彻底地解决中国人民乃至人类的疾苦。

金融界10月25日消息，申联生物披露投资者关系活动记录表显示，公司的mRNA技术在兽用生物制品领域对动物传染病的防治具有巨大潜力，优点包括更易于多联多价疫苗的开发，研发时间短，量产高，生物安全风险低，可更有效诱导细胞免疫和体液免疫等。公司积极推进mRNA技术在宠物疫苗、治疗药品以及未被完全满足的临床需求的重大动 ...